The direct and indirect costs of untreated insomnia in adults in the United States

Sleep

Volumn 30, Issue 3, 2007, Pages 263-273

  Ozminkowski, Ronald J ^a,b   Wang, Shaohung ^b   Walsh, James K ^c  

^a Department of Obstetrics Gynecology   (United States)

^b MEDSTAT GROUP   (United States)

^c Sleep Medicine and Research Center   (United States)

Author keywords

Burden of illness; Cost; Insomnia

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ANTIPYRETIC AGENT; ESTAZOLAM; FLURAZEPAM; GASTROINTESTINAL AGENT; MIRTAZAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; QUAZEPAM; TEMAZEPAM; TRAZODONE; TRIAZOLAM; ZALEPLON; ZOLPIDEM TARTRATE;

ABSENTEEISM; ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

EID: 33947695769     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/30.3.263     Document Type: Article

References (40)

1. nd ed.: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine, 2005.
2. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111.
3. Ohayon MM. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiat Res 1997;31:333-46.
4. Buysse DJ, Reynolds CF, Kupfer DJ, et al. Clinical diagnoses in 216 insomnia patients using the international classification of sleep disorder (ICSD), DSM-IV, and ICD-10 categories: a report from the APA/NIMH DSM-IV field trial. Sleep 1994;17:630-7.
5. Roth T. The relationship between psychiatric diseases and insomnia. Int J Clin Pract 2001(Suppl 116):3-8.
6. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998;158:1099-1107.
7. Benca RM. Consequences of insomnia and its therapies. J Clin Psychiat 2001;62(Suppl 10):33-8.
8. National Institutes of Health State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005;28:1049-57.
9. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995;18:425-32.
10. Mallon I, Broman JE, Hetta J. Relationship between insomnia, depression, and mortality: a 12-year follow-up of older adults in the community. Int Psychogeriatr 2000;12:295-306.
11. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002;51:229-235.
12. Zammit GK, Weiner J, Damata N, et al. Quality of life in people with insomnia. Sleep 1999;22(Suppl 2):S379-S385.
13. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989;262:1479-84.
14. Chang PP, Ford DE, Mead LA, et al. Insomnia in young men and subsequent depression: the Johns Hopkins Precursors Study. Am J Epidemiol 1997;146:105-14.
15. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004;65(Suppl 8):13-19.
16. Hatoum HT, Dong SX, Darnia CM, Wong JM, Mendelson WR. Insomnia, health-related quality of life, and healthcare resource consumption: a study of managed care enrollees. Pharmacoeconomics 1998;14:629-47.
17. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417-23.
18. Leger D, Guilleminault C, Bader G, Levey E, Palliard M. Medical and socio-professional impact of insomnia. Sleep 2002;25:625-9.
19. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22(Suppl 2):S386-S393.
20. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia: an overview. Pharmacoeconomics 1996;10(Suppl 1):1-14.
21. Laschober M. Trends in Medicare supplemental insurance and prescription drug benefits, 1996-2001. Data update prepared for the Henry J. Kaiser Family Foundation. Bearing Point, Inc., June 2004.
22. Charlson M, Pompei P, Ales A, MacKenzie R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83.
23. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care 2006;12:110-19.
24. Ashcraft ML, Fries BE, Nerenz DR, et al. A psychiatric patient classification system: an alternative to diagnosis-related groups. Med Care 1989;27:543-57.
25. Brunello N, Armitage R, Feinberg I, et al. Depression and sleep disorders: Clinical relevance, economic burden, and pharmacological treatment. Neuropsychobiology 2000;42:107-19.
26. Miller ME, Sulvetta MB, Englert E. Service mix in the hospital outpatient department: implications for Medicare payment reform. Health Serv Res 1995;30:59-78.
27. Fisher ES, Wennberg JE, Stukel TA, et al. Associations among hospital capacity, utilization, and mortality of US Medicare beneficiaries, controlling for sociodemographic factors. Health Serv Res 2000;34:1351-62.
28. Luft HA, ed. HMOs and the elderly. Ann Arbor, MI: Health Administration Press, 1994.
29. Drake C, Fisher L. Prognostic models and the propensity score. Int J Epidemiol 1995;24:183-7.
30. McCaffrey D, Ridgeway G, Moral A. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods 2004;9:403-25.
31. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ 1998;17:247-81.
32. Heckman JJ, Hidehiko I, Prieti T. Matching as an econometric evaluation estimator: evidence from a job training program. Rev Econ Stud 1997;64:605-54.
33. Goetzel RZ, Guindon A, Turshen I, Ozminkowski R. Health and productivity management: establishing key performance measures, benchmarks, and best practices. J Occup Environ Med 2001;43:10-17.
34. Simon G, Ormel J, VonKorff M, Barlow W. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995;152:352-7.
35. Leger D, Massuel MA, Mellaine A, and the SISYPHE Study Group. Professional correlates of insomnia. Sleep 2006;29:171-8.
36. Godet-Cayre V, Pelletier-Fluery N, Le Valliant M, Dinet J, Massual MA, Leger D. Insomnia and absenteeism at work. Who pays the cost? Sleep 2006;29:179-84.
37. Leger D. Public health and insomnia: economic impact. Sleep 2000;(Suppl 3):S69-S76.
38. Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 2004;27:1441-2.
39. Morelock RJ, Tan M, Mitchell DY. Patient characteristics and patterns of drug use for sleep complaints in the United States: Analysis of National Ambulatory Medical Care Survey data, 1997-2002. Clin Ther 2006;28:1044-53.
40. Fronstin P. Features of employment-based health plans. EBRI Issue Brief 1998;201:1-21.